Balaxi Pharmaceuticals Limited (BALAXI) AI Stock Analysis

• Market Cap: ₹1.31B
• Dividend Yield: N/A
• Average Volume (3M): 75.37K
• Price to Earnings (P/E): 112.0
• Beta (1Y): 1.06
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 55,207,500
• 10 Day Avg. Volume: 158,740
• 30 Day Avg. Volume: 75,367
• PEG Ratio: -0.01
• Price to Book (P/B): 1.60
• Price to Sales (P/S): 1.28
• P/FCF Ratio: -6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: ₹24.00 ▼(-11.31% Downside)
• Action: Reiterated Date: 04/03/26
• Date: Action: Reiterated 04/03/26

The score is held back primarily by an expensive valuation (very high P/E) and weak technical setup (negative MACD and price still below long-term moving averages). Financial performance is a partial offset due to strong revenue growth and a generally solid balance sheet, but volatile net income and negative free cash flow in the latest year are meaningful risks.

Positive Factors

Revenue Growth Trajectory

Sustained top-line growth between 2024 and 2025 indicates expanding product uptake and distribution reach. Over 2-6 months this supports scale advantages, enables reinvestment in marketing or capacity, and provides a buffer against cyclical downturns if execution and margins hold.

Negative Factors

Negative Free Cash Flow

A swing to negative free cash flow driven by weaker operating cash flow and higher capex raises sustainability concerns. Persisting cash deficits can force external financing, constrain investment or working capital, and increase refinancing or dilution risk within a 2-6 month planning horizon.

Balaxi Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardw...

Read more

Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardw...

How the Company Makes Money

Balaxi Pharmaceuticals Limited primarily makes money by selling pharmaceutical products (formulations) to customers through its marketing and distribution activities, generating revenue from product sales. More specific details on the company’s re...

Read more

Balaxi Pharmaceuticals Limited primarily makes money by selling pharmaceutical products (formulations) to customers through its marketing and distribution activities, generating revenue from product sales. More specific details on the company’s re...

Balaxi Pharmaceuticals Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.76B	2.89B	2.41B	3.36B	2.79B	2.31B
Gross Profit	1.24B	1.27B	1.13B	1.34B	837.91M	591.85M
EBITDA	231.75M	305.64M	456.59M	603.82M	560.20M	449.86M
Net Income	144.99M	250.70M	-23.87M	459.63M	476.58M	381.37M
Balance Sheet
Total Assets	3.22B	3.10B	2.58B	2.40B	1.76B	996.80M
Cash, Cash Equivalents and Short-Term Investments	388.49M	394.00M	622.91M	282.17M	71.93M	16.69M
Total Debt	565.23M	534.25M	194.04M	133.06M	36.38M	36.59M
Total Liabilities	844.30M	786.06M	569.79M	567.89M	633.07M	347.00M
Stockholders Equity	2.38B	2.32B	2.01B	1.83B	1.13B	649.80M
Cash Flow
Free Cash Flow	25.78M	-589.01M	32.97M	-89.05M	68.00M	-25.53M
Operating Cash Flow	149.66M	-377.82M	48.66M	60.75M	341.44M	32.00K
Investing Cash Flow	-167.16M	-217.64M	-10.46M	-105.65M	-284.48M	-59.73M
Financing Cash Flow	11.99M	366.55M	302.54M	255.13M	-1.63M	36.46M

Balaxi Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 27.06
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Neutral. The current price of 27.06 is above the 20-day moving average (MA) of 19.24, above the 50-day MA of 20.69, and below the 200-day MA of 36.01, indicating a neutral trend. The MACD of 0.51 indicates Negative momentum. The RSI at 62.17 is Neutral, neither overbought nor oversold. The STOCH value of 88.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BALAXI.

Balaxi Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOFILCHEM	56 Neutral	₹550.71M	172.45	―	―	36.76%	433.63%
BALAXI	53 Neutral	₹1.31B	111.96	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LASA	45 Neutral	₹381.27M	-4.63	―	―	-20.40%	-59.20%
VIVIMEDLAB	39 Underperform	₹558.01M	-2.21	―	―	-22.42%	21.83%

Balaxi Pharmaceuticals Limited Corporate Events